J.-P. Bronowicki

Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial

Xavier Forns, Eric Lawitz, Stefan Zeuzem et al. · Gastroenterology · 2014 · 256 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Early Administration of Vapreotide for Variceal Bleeding in Patients with Cirrhosis

Paul Calès, Claude Masliah, Brigitte Bernard et al. · New England Journal of Medicine · 2001 · 241 citations

Medicine, Pharmacotherapy, Hemostasis +13

Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process

Xavier Adhoute, Guillaume Pénaranda, Sébastien Naudé et al. · Journal of Hepatology · 2014 · 170 citations

Business, Educational Assessment, Decision Analysis +2

Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial

Marc Bourlière, Pascaline Rabiéga, Nathalie Ganne‐Carrié et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 119 citations

Pharmacy, Immunology, Pharmacotherapy +17

8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)

C. Hézode, Céline Dorival, Fabien Zoulim et al. · Journal of Hepatology · 2012 · 88 citations

Pharmacy, Pharmacotherapy, Hepatitis Pharmacotherapy +10